Sitagliptin-Metformin Sandoz

Initial therapy in adult patients w/ type 2 DM to improve glycemic control when diet & exercise do not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in adult patients w/ type 2 DM who are not adequately controlled on metformin or sitagliptin alone or those already being treated w/ combination of sitagliptin & metformin. In combination w/ sulfonylurea (ie, triple combination therapy) as adjunct to diet & exercise in adult patients w/ type 2 DM inadequately controlled w/ any 2 of the 3 agents (metformin, sitagliptin or sulfonylurea). Add-on to insulin (ie, triple combination therapy) as adjunct to diet & exercise to improve glycemic control in patients when insulin & metformin alone do not provide adequate glycemic control.

Individualized dosage. Patient inadequately controlled w/ diet & exercise alone; on sitagliptin monotherapy Starting dose: 50/500 mg bd. May titrate up to 50/1,000 mg bd if w/ inadequate glycemic control. Patient inadequately controlled on metformin monotherapy Starting dose: Sitagliptin 50 mg bd (total daily dose: 100 mg) & dose of metformin already being taken. Patient inadequately controlled on dual combination therapy w/ any 2 of the following antihyperglycemics: sitagliptin, metformin or sulfonylurea Starting dose: Sitagliptin 50 mg bd (total daily dose: 100 mg). Consider glycemic control & current dose (if any) in determining starting dose of metformin. May require lower sulfonylurea doses if currently on or initiating sulfonylurea. Patient inadequately controlled on dual combination therapy w/ insulin & metformin Starting dose: Sitagliptin 50 mg bd (total daily dose: 100 mg). Consider glycemic control & current dose (if any) in determining starting dose of metformin. May require lower insulin doses if currently on or initiating insulin therapy.

Should be taken with food.

Hypersensitivity to metformin HCl. History of serious hypersensitivity reaction to sitagliptin-metformin or sitagliptin (eg, anaphylaxis or angioedema). Acute or chronic metabolic acidosis including diabetic ketoacidosis. Severe renal impairment (eGFR <30 mL/min/1.73 m²).

Antidiabetic Agents

A10BD07 - metformin and sitagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.

POM